Hire Small Cap Investor Relations Firm

Investor Lead Generation is on the Mind of Most Every Company Looking to Grow Their Shareholder Bases.

Small Cap Investor Relations Firm

Founded in 2005, Positive Stocks is the Small Cap Investor Relations Firm. Positive Stocks, a marketing firm specializing in small-cap and micro-cap companies trading on the OTC Markets.Strategic Growth Consultants working with small public companies

San Diego, (  – Retained Positive Stocks, Inc. For Strategic Growth Counseling….a cutting-edge marketing firm specializing in small-cap and micro-cap companies trading on the OTC Markets, as their strategic growth consultant. 

Under the terms of the agreement, Positive Stocks will expand presence with the nation’s brokerage and investment community, manage its growing shareholder bases, develop and implement the Company’s overall corporate communications strategy.

Positive Stocks  will also tap into its  industry network to assist with product development, identifying top quality suppliers and brand awareness.

Positive Stocks is a cutting-edge marketing firm focused on Small-cap and Micro-cap companies trading on the OTC Markets. We are passionate about helping undervalued companies reach the audience they deserve. We know market trends. We are informed about the regulatory landscape. It’s our business to understand the mindset of today’s investors and how to deliver our clients’ message.

We highlight Small Cap Stocks that are geared to ramp up. platform is primarily used to: (1) create and distribute audio/video based content related to a particular private or public company or an industry in which a company conducts business; (2) append interview-related and other rich media content to traditional press releases; and (3) for registered investment professionals only, to add interview-based audio & video content to financial research. content is distributed to 1M individuals online and over 60,000 financial professionals, including North American and international buy-side analysts, investment research professionals and portfolio managers. 

Positive Stocks specializes in covering Small Cap Stocks & providing Small Cap Investor Awareness Programs.  Positive Stocks also offers investing tools to help investors make informed decisions about the small cap stocks they are interested in. 

Follow Positive Stocks for investment news, expert views, insights & commentary. Positive Stocks is a capital market services & investment research firm based out of San Diego with a proven track record of positively identifying and launching quick-coverage of highly potential small cap & mid cap stocks at an early stage. Meet the CEO’s of some of the most ambitious small cap public companies and influencers within and around the industry.

Podcast & Internet Radio Exclusive Audio & Video Interviews now Featured at &

San Diego,CA,  —, Inc. and  , a technology-driven lead generation and broadcasting company, today announced that a new audio interview with the Company is now available. The interview can be heard at

About Positive Stocks

Positive Stocks is a capital market services & investment research firm based out of San Diego , with a proven track record of positively identifying and launching quick-coverage of highly potential small cap & mid cap stocks at an early stage. We review potential positive catalysts that might push stocks higher. Follow us for investment news, expert views, insights & commentary.

Meet the CEO’s of some of the most ambitious small cap public companies and influencers within and around the industry.

Do you want a partner who can raise your market profile, boost value and liquidity and give you access to the financiers and intermediaries who want to hear your story?

For more, see our online exposure platform at



Safe Harbor Statement

The matters discussed, particularly information regarding future revenue, earnings, business plans and goals, consist of forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are subject to the safe harbor created by these sections and involve risks and uncertainties, which could cause actual results to differ materially from the forward-looking information. Such statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. These statements are based on assumptions and estimates that management believes are reasonable based on currently available information; however, management’s assumptions and the Company’s future performance are both subject to a wide range of business risks and uncertainties, and there is no assurance that these goals and projections can or will be met. Any number of factors could cause actual results to differ materially. The Company undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking information contained herein is subject to the risk factors and uncertainties described in the Company’s filings with the Securities and Exchange Commission, which risk factors and uncertainties are incorporated by reference as though fully set forth herein.

CBD Products Gain Attention as Chronic Pain Incidences Rises

NEW YORK, Feb. 11, 2019 /PRNewswire/ — Chronic pain is among one of America’s most commonly present medical conditions. Within the U.S., approximately 70 million suffered from moderate to high levels of chronic pain in 2016, according to data by the National Health Interview Survey. As a result, many were prescribed opioids as a treatment to mitigate the pain. However, in the long run, the mass prescription of opioids had resulted in an epidemic. In 2017, there were 47,600 cases related to opioid overdose which resulted in death out of the reported 70,200 overall overdose incidents. The rising number of cases prompted many countries to pass medical cannabis laws in order to reduce the number of people dependent on opioids. The therapeutic effects of cannabis are known to suppress pain, but are also linked to treating other medical cases such as cancer and epilepsy. Although, due to the lack of large-scale clinical trials, cannabis is not yet recognized as medicinal by the U.S. Food and Drug Administration. Now however, many companies are pouring investments in the industry to further develop the research and global expansion of cannabis. According to data compiled by Verified Market Intelligence, the global marijuana market was valued at USD 42.20 Billion in 2017 and is projected to reach USD 466.81 Billion. Additionally, the market is expected to grow at a CAGR of 35.3% throughout the forecast period from 2018 to 2025. Weekend Unlimited Inc. (OTC:WKULF) (CSE:POT), VIVO Cannabis Inc. (OTC:VVCIF), Nightfood Holdings, Inc. (OTC:NGTF), MYM Nutraceuticals Inc. (OTC:MYMMF) (CSE:MYM), PotNetwork Holdings, Inc. (OTC:POTN)

Despite the issue of federal legality revolving around medical cannabis, there are currently 33 states and the District of Columbia that have legalized cannabis for medical use. States are also allowing the use of many cannabis derivatives, such as CBD (cannabidiol), CBN (cannabinol) and THC (delta-9-tetrahydrocannabinol). CBD is one of the fastest growing segments in the cannabis market because it is the non-psychoactive derivative of cannabis and companies involved in both the medical and recreational markets are using CBD within their products. Hemp-derived CBD’s effects had even prompted government regulators to remove it from the list of Schedule 1 drugs, even though other cannabis components like THC still remain on the list. “CBD has a number of known properties beneficial to the human condition, and research is just beginning,” Aster Farms President Sam Ludwig told Civilized. “There are two markets for CBD: as a supplement, mild pain reliever and relaxant, and in larger doses, as a truly beneficial remedy for a variety of serious illnesses. There is no doubt it will be dominant supplement for years to come.”

Weekend Unlimited Inc. (OTC:WKULF) also listed on the Canadian Securities Exchange under the ticker (CSE:POT). Earlier this morning the company announced breaking news that, “announces the appointment of Mr. Karl Schmieder, MS/MFA., to the role of Director, Business Development and Tom Wisniewski, Vice President Sales Operations. As an executive and entrepreneur, Mr. Schmieder brings more than 25 years of business development success in biopharmaceutical and internet industries. Mr. Wisniewski brings more than 20 years of sales expertise in consumer-packaged goods, investment, real estate, telecommunications industries.

“Karl is a strategic thinker who will contribute to the development of new products, partnerships and services. Tom brings diverse leadership experience in sales and operations and will help drive our national and international growth,” said Mr. Paul Chu, President and Chief Executive Officer, Weekend Unlimited. “The addition of Karl and Tom helps strengthen Weekend’s management as we execute our growth strategy,” added Mr. Chu.

Mr. Schmieder co-founded messagingLAB, a strategy and marketing communications firm focused on the life sciences. He has successfully launched biotechnology companies and pharmaceutical products and services. He has held executive and business development positions at emerging digital health and leading strategy communications consulting firms.

Mr. Wisniewski is seasoned sales professional with extensive experience nationally and internationally. He has served as managing director of Rocket Holdings, a private investment and real estate group. In addition, Mr. Wisniewski served as field account manager at VHA Corporation and sales manager at Abmnus. Mr. Wisniewski is a pioneer in …

Full story available on

CBD Market Could Outpace Entire Marijuana Market News Commentary

PALM BEACH, Florida, Feb. 7, 2019 /PRNewswire/ — In the horse race to revenues, it seems that CBD infused products market may outpace the cannabis market, with the passage of the 2018 Farm Bill kicking it ahead across the finish line! A report from a cannabis industry analyst, as reported in The Rolling Stone magazine, says: “For years, experts have predicted that if the cannabis industry expands at its current rate, the American market will reach $20 billion by 2020. But it turns out that one market is spinning off into a mega-industry of its own: according to a new estimate from cannabis industry analysts the Brightfield Group, the hemp-CBD market alone could hit $22 billion by 2022.” In fact the Rolling Stone sub-headline sums it up the reason why: “Looking forward to relaxed hemp regulations, a new analysis estimates that the CBD market could explode — and outpace marijuana.”. Previously, CBD products have been available mostly in head shops, with a few doctors recommending it for various maladies. But in 2017 and 2018, the products spread to natural food stores, beauty aisles, cafés and doctors offices. So far the industry is on track to hit $591 million in 2018, and thanks to a number of factors — including, surprisingly, Senate Majority Leader Mitch McConnell — that could increase 40 times in the next four years.”   Active companies in the markets this week include The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF), Aphria Inc. (NYSE:APHA) (TSX:APHA), Harvest Health & Recreation Inc. (CSE:HARV) (OTC:HRVOF), 1933 Industries Inc. (CSE:TGIF) (OTC:TGIFF), MedMen Enterprises Inc. (CSE:MMEN) (OTC:MMNFF).

“According to the (Brightfield’s) projections, there would be increases in just about every sector that sells CBD — from dispensaries to smoke shops to medical companies. But perhaps the biggest push, according to Gomez, would be from big-box retailers and national chains who have been eager to get in on the lifestyle craze but have felt stifled by the (older )regulations (that have been replaced by the passage of The 2018 Farm Bill.”

The Yield Growth Corp.



   Yield Growth Corp is pleased to announced that its e-commerce platform will now sell its Urban Juve cannabis Sativa hemp root oil-based products in the United States thanks to the adoption of the 2017 U.S. Farm Bill.  

Urban Juve products are now available for sale in the U.S. via the site  In addition, the company has plans to sell its products through U.S. retailers such as pharmacies, naturopaths, clinics, salons, spas, wellness and beauty stores.

“U.S. distribution is a cornerstone of our sales strategy for all our brands. Already we have a deal in place to sell our THC and CBD infused products through …

Full story available on



Here is one noteworthy achievement in the stock trade showcase. The interest in penny stocks has gotten a ton of positive result when you realize the one to manage. 

Various penny stocks, particularly those that trade for divisions of a penny is pitifully traded. They can transform into the goal of stock promoters and manipulators. These controllers first purchase immense measures of stock, by then misleadingly explode the offer expense through false and misleading positive explanations. This is suggested as a “siphon and dump” plot. The siphon and dump is a sort of microcap stock distortion. 

We will examine the best penny stocks to keep an eye out for. 

Valhi Incorporated (VHI) 

Valhi, Inc is a holding association which participates in the creation and advancing of titanium dioxide colors (an assurance utilized from discoloration under brilliant (UV) light in revealed applications. It is used in things, for instance, paints and coatings, including coatings and enamels, plastics, paper, inks, strands, sustenances, pharmaceuticals, and magnificence care items) saw a noteworthy twofold best precedent from 2011 to 2014, tumbling to $10.50. The stock hit a 13-year low in February 2016, by then invigorated toward the start of November to a 52-week high of $4.10 by January 2017. 

The stock tumbled to $3.00 in February before renewing in the second half of April, where it by and by trades near a two-month high. The stock needs to rally above $3.90 to keep a bearish diving triangle. A triangle breakout will bolster continuing with quality. 

In the cannabis stock, we have; 

The Canopy Growth Corporations; 

This is the main Canadian Cannabis stock, with a market top of $13.1 billion. In May, it was recorded on the NYSE and turned into the turned into the biggest organization on the planet to openly exchange cannabis. It has different brands, with the point of implementing its inclusion in the restorative and recreational viewpoint. The organization’s most well-known brand is Tweed. Tweed has a relationship with Snoop Dogg. It recorded an income of 77.9 million Canadian follows in March 2018. 

In late 2017, Canopy sold a 9.9% stake to Constellation Brand, the creator of Corona lager. 

They at present have a normal volume of 10,325,804. 

In the crypto industry, one stock to put resources into is; 


The crypto space particularly takes after other nascent organizations of yesteryear. A couple of pioneers rise early, trailed by the straggling leftovers of the pack. After some time, that head start normally exhibits a basic ideal position. Ethereum, the second-most noteworthy propelled cash behind bitcoin, is adequately a champion among the best cryptographic types of cash to buy, basically in light of the fact that building an upgraded game plan of electronic endeavors without it is supreme reckless. Nobody grasps what will create as the predominant computerized cash 20 or a long time from now, any way you’d be crazy not to have the best picks. It takes after obtaining both Apple (AAPL) and Microsoft Corp. (MSFT) amid the 1990s, just to help your bets. Turned out altogether well. 

The Southcross Energy Partners 

The SXE association opened up to the world in 2012 in the low 20s and accomplished a record-breaking high four months afterward at $26.49. The stock continued when the base dropped out of the essentialness publicize, hitting an unequaled low of 38 pennies in February 2016. 

The January rally pushed the stock to a 17-month high before pivoting above $4.75 this month and is at present slanting at higher lows. A test at $4.00 should offer a by and large safe buy opportunity, possibly offering a course to a firmer obstacle above $6.30. Exclusive Interview With Chairman and CEO Denis Corin of Q BioMed Inc. Live From Times Square in New York City

NEW YORK, Feb. 5, 2019 /PRNewswire/ —, a respected source in the financial news media space located on Wall Street, today announces an exclusive video interview with Q Biomed Inc. (OTCQB:QBIO) Chairman and CEO, Denis Corin from the floor of the NASDAQ MarketSite at Times Square New York City.

Mr. Corin shares with us his vision of Company’s growth and why he believes 2019 and beyond are essential years for Q BioMed Inc. The interview provides unique insight into the Company’s latest corporate developments, updates on recently-achieved milestones, and current upcoming catalyst. Additionally, Mr. Corin provides his perspective on how Q BioMed Inc. is well positioned to build upon its current pipelines and creating continued shareholder value.

Mr. Denis D. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental in building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also served as a Management Consultant to the executives and board of TapImmune Inc. (NASD: TPIV), a clinical stage immune -oncology company through 2014, He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.

Watch the full HD Video Interview now to learn more about the buzz surrounding Q BioMed Inc. (OTCQB:QBIO)

Click Here for full HD video interview:

About Q BioMed Inc. (

Q BioMed aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company’s FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019.  Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of …

Full story available on